RM-NBS / Neurobehavioural and neuroendocrine signalling
P021
Also known as: Peptide 021 · P21 supplier shorthand · CNTF peptide mimetic
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
P021 is a modified peptide mimetic derived from a ciliary neurotrophic factor region. Supplier use of the shorter label P21 can refer to other molecules, so a full sequence and modification record is required before attaching this literature.
Evidence position
Published cellular and animal work supports Grade C. No direct human interventional record was identified for the defined P021 compound.
What the record does not establish
Preclinical results do not establish human effects and cannot validate a product labeled only P21.
Sources
- 01Prevention of dendritic and synaptic deficits with P021PubMed
- Shows
- Long-duration study in a transgenic mouse model describing P021 composition and outcomes
- Does not show
- Mouse model only; not a human trial or evidence about an ambiguously labeled P21 product
- 02Rescue of cognitive aging by a neurogenic and neurotrophic compoundPubMed
- Shows
- Preclinical rat research on P021-related neurogenesis and synaptic measures
- Does not show
- Animal model and a defined research compound only
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBMED / FOUND RECORDS
- Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction.Journal of Alzheimer's disease : JAD / 2021PMID 34057082 / DOI 10.3233/JAD-201599